Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022042329 - APPLICATION OF TIGIT IMMUNOADHESIN IN REGULATING TUMOR IMMUNITY AND REGULATING ANGIOGENESIS PRODUCTS

Publication Number WO/2022/042329
Publication Date 03.03.2022
International Application No. PCT/CN2021/112374
International Filing Date 13.08.2021
IPC
A61K 38/17 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61K 45/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 37/04 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
CPC
A61K 38/1709
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
1703from vertebrates
1709from mammals
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 37/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
Applicants
  • 沣潮医药科技(上海)有限公司 PHARCHOICE THERAPEUTICS INC [CN]/[CN]
Inventors
  • 傅文燕 FU, Wenyan
  • 胡适 HU, Shi
Agents
  • 成都顶峰专利事务所(普通合伙) CHENGDU DINGFENG PATENT AGENCY (GENERAL PARTNER)
Priority Data
202010862713.425.08.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) APPLICATION OF TIGIT IMMUNOADHESIN IN REGULATING TUMOR IMMUNITY AND REGULATING ANGIOGENESIS PRODUCTS
(FR) APPLICATION DE L'IMMUNOADHÉSINE TIGIT DANS LA RÉGULATION DE L'IMMUNITÉ TUMORALE ET LA RÉGULATION DE PRODUITS DE L'ANGIOGENÈSE
(ZH) TIGIT免疫粘附素在调控肿瘤免疫及调节血管生成产品中的应用
Abstract
(EN) The present invention relates to the technical field of biomedical engineering. Disclosed is a new use of TIGIT immunoadhesin in regulating tumor immunity and regulating angiogenesis products. By means of experimental verification, the TIGIT immunoadhesin can effectively enhance immune cells to kill and identify tumor cells, can enhance the growth inhibition of the immune cells on tumor tissues, can improve immunosuppression signals in the tumor tissues to break a tumor immunosuppression micro-environment, and moreover, can improve the hypoxia condition of the tumor tissues so as to increase the blood flow supply and change the tumor growth environment, thus hammering the tumor cells in two ways. On the other hand, the TIGIT immunoadhesin can stimulate angiogenesis, thereby enhancing the healing of newborn tissues, providing a certain direction for the treatment of vascular injury diseases, and widening the clinical application prospect and range of the TIGIT immunoadhesin.
(FR) La présente invention se rapporte au domaine technique du génie biomédical. Est divulguée, une nouvelle utilisation de l'immunoadhésine TIGIT dans la régulation de l'immunité tumorale et la régulation de produits de l'angiogenèse. Au moyen d'une vérification expérimentale, l'immunoadhésine TIGIT peut renforcer efficacement les cellules immunitaires pour identifier et tuer des cellules tumorales, peut améliorer l'inhibition de la croissance des cellules immunitaires sur des tissus tumoraux, peut améliorer les signaux d'immunosuppression dans les tissus tumoraux pour briser un micro-environnement d'immunosuppression tumorale, et en outre, peut améliorer l'état d'hypoxie des tissus tumoraux de façon à augmenter l'alimentation en flux sanguin et à modifier l'environnement de croissance tumorale, ce qui permet de pilonner les cellules tumorales de deux manières. D'autre part, l'immunoadhésine TIGIT peut stimuler l'angiogenèse, améliorant ainsi la cicatrisation des nouveaux tissus, fournissant une certaine direction pour le traitement de maladies à lésion vasculaire, et élargissant les perspectives et la plage d'application clinique de l'immunoadhésine TIGIT.
(ZH) 涉及生物医药工程技术领域,公开了TIGIT免疫粘附素在调控肿瘤免疫及调节血管生成产品中的新用途,通过实验验证,TIGIT免疫粘附素能有效增强免疫细胞杀伤、识别肿瘤细胞;增强免疫细胞对肿瘤组织的生长抑制;改善肿瘤组织内免疫抑制信号,打破肿瘤免疫抑制微环境;同时还能改善肿瘤组织缺氧状况,增加血流供应,改变肿瘤生长环境,从两方面锤击肿瘤细胞。另一方面,TIGIT免疫黏附素可以刺激血管新生,增强新生组织愈合,为血管损伤性疾病的治疗提供了一定方向,扩大了TIGIT免疫粘附素的临床应用前景和范围。
Latest bibliographic data on file with the International Bureau